FDA Approves Tagraxofusp for Rare Hematologic Cancer

December 21, 2018 – The FDA has approved tagraxofusp-erzs (SL-401) infusion for the treatment of adult and pediatric patients, aged ≥2 years, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval is based on data from 2 cohorts of a multicenter, open-label, nonrandomized single-arm trial. In the first cohort, 7 of 13 patients (54%) treated with tagraxofusp achieved a complete remission (CR) or CR with a skin abnormality not indicative of active … (leggi tutto)